The accelerated approval of Trodelvy for patients with metastatic urothelial cancer has been voluntarily withdrawn.

the most common form of bladder cancer. The results of the TROPiCS-04 study compared Trodelvy (sacituzumab govitecan) to chemotherapy as second-line treatment for patients with locally advanced or ...

Trodelvy (sacituzumab govitecan) has been approved for locally ... have been withdrawn in bladder cancer as a result. Gilead said Trodelvy’s safety profile in the TROPHY study is consistent ...

Bladder cancer is a cancer that forms in tissues of the bladder. Most bladder cancers are transitional cell carcinomas (cancer that begins in cells that normally make up the inner lining of the ...

The subtypes investigated in bladder cancer were CK19, CK20 and CK7 IHC/RT-PCR CK20: 56–46% [98,99]; CK7: 100% [99]; CK1: 93.1% [101] Association of CK19 with UPII detected pN0 patients with ...

The Impact of the COVID-19 Pandemic on Urologic Cancer Care ...

A Michigan State University researcher's new model for studying breast cancer could help scientists better understand why and where cancer metastasizes. A new randomized controlled trial out of ...

Huntsman Cancer Institute’s Urologic Cancers Program provides comprehensive, compassionate, state-of-the-art care for people with these cancers. Our experts treat and diagnose all types of urologic ...

The phase 3 ENVISION trial met its primary end point by demonstrating a 79.6% complete response rate at 3 months following the first instillation of the therapy.

(UroToday.com) The 2024 European Association of Urology (EAU) annual meeting featured a game changing session on prime time for adjuvant treatment in locally advanced bladder cancer, and a ...

Nov. 11, 2024 — Researchers have discovered a new way in which RAS genes, which are commonly mutated in cancer, may drive tumor growth beyond their well-known role in signaling at the cell surface.

Barbara O’Brien, MD, discussed findings and implications from the phase 2 TBCRC049 study evaluating the combination of tucatinib, trastuzumab, and capecitabine in HER2-positive breast cancer with ...